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Stage-dependent loss of cortical
gyrification as Parkinson disease “unfolds”
ABSTRACT
Objective: Nigrostriatal terminal losses are known to progress most rapidly in early-stage Parkin-
son disease (PD) and then plateau, whereas cortical pathology continues and may provide a better
marker of PD progression in later stages. We investigated cortical gyrification indices in patients
with different durations of PD, since cortical folding may capture complex processes involving
transverse forces of neuronal sheets or underlying axonal connectivity.
Methods: Longitudinal cohort structural MRI were obtained at baseline, 18 months, and 36
months from 70 patients with PD without dementia and 70 control participants. Cortical local
gyrification index (LGI) was compared between controls and PD subgroups based upon duration
of illness (DOI, ,1 year [PDE, n 5 17], 1–5 years [PDM, n 5 19], .5 years [PDL, n 5 24]) and
adjusted using false discovery rate. Associations between LGI and clinical measurements were
assessed using multiple linear regression. Areas having significantly reduced LGI also were ana-
lyzed using baseline data from a newly established cohort (PD n 5 87, control n 5 66) to validate
our findings.
Results: In the longitudinal cohort, PDL had significantly reduced overall gyrification, and bilater-
ally in the inferior parietal, postcentral, precentral, superior frontal, and supramarginal areas,
compared to controls (p , 0.05). Longitudinally, loss of gyrification was accelerated in PDM
participants, compared to controls. LGI showed robust correlations with DOI and also was cor-
related with PD-related clinical measurements. Similar results were obtained in the validation
sample.
Conclusions: Loss of cortical gyrification may be accelerated within the first few years after PD
diagnosis, and become particularly prominent in later stages. Thus, it may provide a metric for
monitoring progression in vivo. Neurology® 2016;86:1143–1151
GLOSSARY
DOI 5 duration of illness; H&Y 5 Hoehn & Yahr; HAM 5 Hamilton Depression Rating Scale; ICV 5 intracranial volume;
LEDD 5 levodopa-equivalent daily dose; LGI 5 local gyrification index; MMSE 5 Mini-Mental State Examination; PD 5
Parkinson disease; PDE 5 Parkinson disease–early; PDM 5 Parkinson disease–middle; PDL 5 Parkinson disease–late;
UPDRS 5 Unified Parkinson’s Disease Rating Scale.
In Parkinson disease (PD), degeneration of dopamine terminals is thought to progress rapidly
within the first few years after diagnosis and then plateau.1 Thus, in more advanced stages of
disease, non-nigrostriatal brain changes may serve as better markers of PD progression. Evidence
suggests that widespread pathologic changes occur in the cortex, including apoptotic signaling,
Lewy pathology, reduction in other neurotransmitters, and interneuron loss.2–4 It is unclear,
however, how cell death relates to the pattern of cortical Lewy pathology, and whether cortical
changes can be used to gauge PD progression.5
Lewy pathology has been documented in specific cortical layers (i.e., preferentially in deep
layers of high-order sensory association areas).5,6 Some previous imaging studies have demon-
strated decreased cortical thickness in PD,7,8 but reported results have been inconsistent and
have not shown robust associations with disease progression in the absence of dementia. These
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inconsistencies may be attributable to several
factors. First, cortical thickness may be less
sensitive in areas where cortex pathology is
not transmural. Second, thickness measure-
ments may not reflect more complex changes
of cortex surface architecture.9 Thus, the dis-
tinction between structural metrics is impor-
tant because they may reflect different aspects
of cortical neurodegeneration. In the current
study, we aimed to characterize changes in cor-
tical gyrification during PD progression by
studying participants with different durations
of illness. We hypothesized that reductions in
gyrification would follow the spatiotemporal
distribution described in studies of Lewy
pathology.5,6
METHODS Longitudinal cohort participants. Patients
with PD (n 5 70) and controls (n 5 70) with a Mini-Mental
State Examination (MMSE) score$26 were selected from a large
cohort study based on matching for baseline age distribution, sex
ratio, and number of follow-up visits (table 1).10,11 Patients with
PD were recruited from a tertiary movement disorders clinic, and
controls from spouses and the local community. PD diagnosis
was confirmed according to published criteria.12 All participants
were free of major and acute medical issues or neurologic
disorders other than PD. All brain images were inspected and
deemed free of any major structural abnormalities. Hamilton
Depression Rating Scale (HAM)13 scores were obtained at each
visit. PD subgroups were assigned for comparisons to controls
based upon duration of illness (DOI), defined as the number of
years since diagnosis in the same fashion that we had done
previously (PD–early [PDE] [,1 year], PD–middle [PDM]
[1–5 years], PD–late [PDL] [.5 years]).14
Validation study participants. A validation study was con-
ducted using the baseline data from a newly established cohort
under the NIH PD Biomarkers Program (NCT01888185).15
Participants were recruited in a similar manner as the longitudinal
cohort participants, except there were more advanced-stage
patients. The original population of validation participants
included 104 patients with PD and 71 controls. Participants
having signs of dementia were excluded using the MMSE score
cutoff described above.
Standard protocol approvals, registrations, and patient
consents. Written informed consent was obtained for all partic-
ipants, in accordance with the Declaration of Helsinki. The
research study protocol was approved by the Penn State Hershey
Institutional Review Board.
Clinical evaluation. Unified Parkinson’s Disease Rating Scale
(UPDRS) motor scores and Hoehn & Yahr (H&Y) stages were
obtained for PD in the “on” medication state at each visit. Lon-
gitudinal cohort UPDRS motor scores were recorded using the
original UPDRS.16 Validation study UPDRS motor scores were
recorded using the revised UPDRS.17 Levodopa-equivalent daily
dose (LEDD) was calculated according to published criteria.18
MRI data acquisition and analysis. All participants were
scanned using a 3.0T MRI scanner (Trio, Siemens Magnetom,
Erlangen, Germany, with an 8-channel phased array head coil)
at baseline, 18 months, and 36 months. A magnetization-
prepared rapid acquisition gradient echo sequence was used to
obtain T1-weighted images with repetition time/echo time 5
1,540/2.34, field of view 5 256 3 256 mm, matrix 5 256 3
256, slice thickness5 1 mm (with no gap), slice number5 176.
T1-weighted images were processed automatically using Free-
Surfer (version 5.1.0).19 The longitudinal pipeline was utilized to
process longitudinal cohort images by first creating unbiased within-
subject templates. The within-subject templates were then used to
initialize image processing (skull stripping, Talairach transforms,
atlas registration, spherical surface maps) for scans at each visit.20,21
Local gyrification index (LGI) was used as a measurement of
cortical folding. Historically, LGI was defined as the ratio of cor-
tical surface over the outer contour (perimeter) of a 2D brain sec-
tion.22 LGI offers a method to quantify gyrification as it varies
across the surface of a 3D cortical mesh (;150,000 vertices).23
For each vertex vi, a circular region of interest was defined on the
mesh surface having radius 25 mm and center vertex vi. Outer
and pial surface areas (AO, AP) were computed as the sum of
surface areas assigned to vertices that fell within the region of
interest. LGI was defined as the ratio of AP/AO. The final com-
putation of LGI at each vertex was calculated by inverse weighting
based upon distance. Thus, the LGI computed for each vertex vi
contains information from both the center vertex vi and vertices
that are nearby. However, this is to be expected, since gyrification
is aimed to represent the combined structural properties of neigh-
boring gyri and the sulci between them.23
Statistical analysis. Sex and age were compared between pa-
tients with PD and controls using Fisher exact test and 2-
sample Student t test, respectively. Analysis of variance was
used to assess differences among PD subgroups or controls. We
performed longitudinal analyses of cortical structure at the vertex
level using a validated framework (spatiotemporal linear mixed
effects model) that leverages covariance among neighboring
vertices and can yield increases in statistical power while providing
good control of false-positive rate.24 Briefly, each hemisphere was
divided into ;30,000 regions of homogenous covariance from
;150,000 vertices. Fast expectation maximization iterations were
applied to obtain more accurate parameter estimates, which were
averaged within each region.25 Hypothesis testing utilized the
Satterthwaite-based approximation of a scaled F statistic. p Values
were adjusted using an expected false discovery rate of 0.05.26,27
The final mixed effects model used for group comparisons
included the following: linear and quadratic terms of age at baseline,
sex, years elapsed since baseline, years of education, HAM at each
visit, intracranial volume (ICV), the terms for PD stages, the respec-
tive interaction terms for PD stages and years elapsed, the term for
interaction between age at baseline and years elapsed, and the term
for interaction between sex and years elapsed. ICVwas included as a
covariate because it was associated with overall LGI (p , 0.0001).
General linear hypothesis testing using the F statistic was uti-
lized to conduct group and subgroup comparisons.28 Overall LGI
was defined as the average of LGI across all cortical vertices.
Regional and overall gyrification indices were analyzed using R
version 3.1.1.29
The relationships between clinical measurements and cortical
structural measures among PD participants at baseline were as-
sessed (1) descriptively using locally weighted regression and
95% bootstrapped confidence regions and (2) quantitatively
using multiple linear regression for each variable of interest inde-
pendently (covariates included age, sex, education years, ICV,
and HAM as appropriate).
The validation study was conducted in cortical areas that were
found to be significantly associated with advanced PD stage in the
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longitudinal cohort. For this analysis, we utilized the bilateral
regional means of LGI for the respective cortical areas. The general
linear model was used to conduct these validation analyses and
included the following variables: linear and quadratic terms of age
at baseline, sex, years of education, HAM, ICV, and the terms
for PD stages. Outliers having extremely low gyrification values
(2 standard deviations , sample mean) were excluded from the
study (1 control, 2 PDM, 2 PDL in the validation sample).
RESULTS Demographic characteristics of study
participants. In the longitudinal cohort, patients with
PD and controls were not significantly different in
age or sex frequencies at any visit (table 1). Controls
had more years of education than patients with PD,
but education did not correlate with any cortical metrics
in either the patients with PD or controls. From the
baseline visit, the 18-month dropout rate was 20.0%
and 17.1% for patients with PD and controls,
respectively, and 14.3% and 10.3%, respectively, from
18 to 36 months. The total number of visits did not
differ between patients with PD and controls (p 5
0.210). The demographic characteristics of those who
dropped out did not differ between patients with PD
Table 1 Demographic and clinical properties of study participants
Control PD overall PDE PDM PDL p Valuea p Valueb
Longitudinal cohort participants
Baseline
No. participants (F, M) 70 (35, 35) 70 (30, 40) 17 (12, 5) 29 (9, 20) 24 (9, 15) 0.498c 0.050c,d
Age, y 61.3 6 6.72 62.4 6 8.00 60.9 6 9.11 61.3 6 7.03 65.0 6 7.90 0.395 0.136
Education, y 16.9 6 2.6 15.8 6 2.6 15.8 6 2.4 15.5 6 2.7 16.0 6 3.1 0.017d 0.099
MMSE 29.4 6 0.85 29.5 6 0.85 29.2 6 1.10 29.1 6 1.31 29.2 6 0.83 0.416 0.169
HAM 3.9 6 2.4 7.5 6 4.1 6.8 6 2.9 7.1 6 4.5 8.3 6 4.2 ,0.0001d ,0.0001d
DOI, y — 4.60 6 4.92 0.48 6 0.29 2.31 6 1.18 10.3 6 4.21 — ,0.0001d
LEDD, mg — 738 6 504 310 6 211 624 6 401 1097 6 481 — ,0.0001d
UPDRS-III — 17.8 6 11.0 11.4 6 8.2 19.8 6 10.4 20.4 6 11.9 — 0.135d
H&Y stage — 1.7 6 0.70 1.4 6 0.63 1.5 6 0.69 2.2 6 0.60 — 0.002d
36 months
No. participants (F, M) 52 (27, 25) 48 (26, 22) 10 (7, 3) 23 (8, 15) 15 (7, 8) 0.556 0.295
Age, y 64.7 6 6.68 67.0 6 7.9 67.9 6 7.18 66.3 6 5.99 68.5 6 7.88 0.100 0.282
Education, y 16.7 6 2.70 15.8 6 2.7 16.4 6 2.67 15.5 6 2.35 15.7 6 3.35 0.086 0.299
DOI, y — 8.01 6 5.10 3.6 6 0.53 5.7 6 1.3 14.4 6 4.29 — ,0.0001d
LEDD, mg — 856 6 605 674 6 283 697 6 456 1304 6 738 — 0.002d
UPDRS-III — 25.7 6 17.3 12.9 6 8.0 23.9 6 14.1 37.5 6 20.3 — 0.006d
H&Y stage — 1.7 6 0.63 1.8 6 0.46 1.9 6 0.40 2.1 6 0.90 — 0.393
Validation study subjects
No. participants (F, M) 66 (33, 33) 87 (41, 46) 18 (7, 11) 36 (19, 17) 33 (15, 18) 0.746 0.784
Age, y 64.6 6 8.77 66.4 6 9.00 64.7 6 9.30 66.8 6 10.14 66.9 6 7.58 0.209 0.497
Education, y 17.2 6 2.9 16.5 6 2.7 16.4 6 2.7 17.0 6 2.7 16.1 6 2.7 0.160 0.265
MMSE 29.1 6 1.18 28.5 6 1.41 28.8 6 1.35 28.6 6 1.46 28.2 6 1.39 0.055 0.189
HAM 2.7 6 3.3 5.5 6 4.8 4.7 6 4.0 3.8 6 3.0 7.8 6 5.8 ,0.0001d ,0.0001d
DOI, y — 5.56 6 5.16 0.48 6 0.26 3.13 6 1.24 10.98 6 4.27 — ,0.0001d
LEDD, mg — 732 6 671 346 6 229 634 6 842 1022 6 468 — 0.002d
UPDRS-III — 27.8 6 17.0 20.2 6 9.2 25.3 6 14.0 34.6 6 20.7 — ,0.0001d
H&Y stage — 1.9 6 0.77 1.5 6 0.62 1.7 6 0.70 2.2 6 0.81 — ,0.0001d
Abbreviations: DOI 5 duration of illness; H&Y 5 Hoehn & Yahr; HAM 5 Hamilton Depression Scale; LEDD 5 levodopa daily equivalent dosage; MMSE 5
Mini-Mental State Examination; PD 5 Parkinson disease; PDE 5 Parkinson disease–early; PDM 5 Parkinson disease–middle; PDL 5 Parkinson disease–late;
UPDRS 5 Unified Parkinson’s Disease Rating Scale.
Measurements presented as mean 6 SD unless otherwise indicated.
ap Values for comparisons between all PD and control participants using 2-sample t tests.
bp Values of analysis of variance across PD subgroups (and controls as appropriate).
cp Values obtained using Fisher exact test.
dStatistically significant.
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and controls. Patients with PD demonstrated the
expected progression of symptoms as reflected by
increased UPDRS-III scores and LEDD. Patients with
PD had increased depression scores compared to
controls (p , 0.0001). Among patients with PD,
disease stage and DOI were significantly associated
with depression scores at all visits (p , 0.0001).
In the validation study sample, PD subgroups and
controls were relatively similar in age, sex frequencies,
and education, but patients with PD had trend-level
lowerMMSE scores compared to controls (p5 0.055).
Longitudinal cohort analysis of cortical gyrification. We
first investigated LGI differences between patients with
PD and controls using vertex-level analyses. Compared
to controls, patients with PD overall had reduced LGI
in the left inferior parietal, superior frontal, frontal pole,
and rostral anterior cingulate, and the right inferior
parietal, precentral, rostral middle frontal, and
fusiform areas (p , 0.05). There were no significant
differences in LGI between completed PD participants
and PD participants lost to follow-up (p $ 0.20).
At baseline and 36-month visits, LGI was not sig-
nificantly reduced in any region in PDE or PDM sub-
groups vs controls. There were substantial differences
in LGI between PDL and controls, however, at baseline
bilaterally in overall LGI, inferior parietal, postcentral,
precentral, superior frontal, and supramarginal areas
(p , 0.05) (figure 1, table 2). At the 36-month visit,
these bilateral differences persisted and also extended to
include bilaterally the transverse temporal, fusiform,
inferior temporal, and pars orbitalis regions (p ,
0.05). Comparisons of LGI between PDL and controls
at the 18-month visit revealed patterns of reduced LGI
that were intermediate between baseline and 36-
month visits. Figure e-1 on the Neurology® Web site
at Neurology.org depicts the longitudinal trajectories
of LGI in cortical regions where LGI was significantly
reduced in PDL.
We next compared LGI among PD subgroups (fig-
ure 1). PDL had reduced LGI at baseline in the pre-
central, postcentral, and superior frontal areas
bilaterally; the left inferior parietal, pars orbitalis, supe-
rior temporal banks, lateral orbitofrontal, and rostral
middle frontal; and right caudal middle frontal areas
compared to combined PDE and PDM subgroups (p,
0.05). At the 36-month visit, there were significant
differences in LGI between PDE/PDM and PDL in
the right precentral and postcentral areas (p , 0.05).
Figure 1 Comparison of local gyrification index between Parkinson disease (PD) subgroups and controls (left)
and among PD subgroups (right) at baseline
PD–late (PDL) participants (duration of illness .5 years) demonstrated significantly reduced gyrification bilaterally in the
inferior parietal, precentral and postcentral, and superior frontal areas, compared to controls at baseline visit (left). PD
subgroup vs control color maps represent adjusted p values using an expected false discovery rate of 0.05. PDL partic-
ipants demonstrated significantly reduced gyrification in several neocortical areas, compared to PD–early (PDE) and
PD–middle (PDM) participants at baseline (right). Post hoc PD subgroup comparison color maps represent significant
b values using a false discovery rate–adjusted p value threshold of 0.05.
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Longitudinal analysis revealed accelerated overall
LGI loss in the PDM subgroup (p, 0.001) and non-
significant accelerated loss in PDE (p 5 0.056) com-
pared to controls. Loss of LGI also was accelerated in
the postcentral, precentral, superior frontal, and
supramarginal areas among PDM (p , 0.05) com-
pared to controls, and nonsignificant accelerated loss
was present in the inferior parietal area (p 5 0.055)
(table 2).
Several clinical measurements were correlated with
LGI. DOI was correlated negatively with overall LGI
and regional LGI of the postcentral, precentral, supe-
rior frontal, and supramarginal areas (p , 0.05).
LEDD was correlated negatively with LGI in all of
the aforementioned areas and UPDRS showed corre-
lations with LGI of the inferior parietal area (p 5
0.026) (figure 2).
Validation study sample analysis of cortical gyrification.
For the validation study, we utilized bilateral averages
of LGI in regions that were shown to be reduced bilat-
erally in the longitudinal cohort study. Compared to
controls, PDL demonstrated significantly lower overall
LGI and in the inferior parietal, postcentral, precentral,
and superior frontal areas (p , 0.05), although the
LGI differences in the supramarginal area did not reach
statistical significance (p 5 0.054) (table 2).
DOI was correlated with overall LGI and regional
LGI of the postcentral, precentral, superior frontal,
and supramarginal areas (p , 0.05), and the correla-
tion for the inferior parietal area did not reach statis-
tical significance (p 5 0.052) (figure 3). UPDRS-III
scores were correlated negatively with overall LGI,
and with regional LGI of the inferior parietal, post-
central, precentral, superior frontal, and supramar-
ginal areas (p , 0.05).
DISCUSSION This study demonstrated that reduced
cortical gyrification is related to disease progression in
participants with PD without dementia. Losses of gyr-
ification were accelerated early after diagnosis, and
became prominent in later stages of disease, suggesting
that measurements of cortical folding may be useful for
Table 2 Comparisons of regional local gyrification index among PD subgroups and controls
PDE PDM PDL
bPDE p Value bPDM p Value bPDL p Value
Longitudinal cohort
LGI in PD subgroups vs controls
Overall LGI 20.008 0.766 20.012 0.581 20.074 0.001a
Inferior parietal 20.048 0.151 20.012 0.661 20.104 0.001a
Postcentral 0.033 0.383 20.028 0.364 20.105 0.002a
Precentral 0.000 0.993 20.023 0.446 20.123 ,0.001a
Superior frontal 20.013 0.536 20.012 0.507 20.076 ,0.001a
Supramarginal 0.019 0.638 0.000 1.000 20.088 0.015a
Annual D LGI in PD subgroups vs controls
Overall LGI 20.005 0.056 20.007 0.000a 20.002 0.257
Inferior parietal 20.007 0.184 20.008 0.055 20.002 0.642
Postcentral 20.005 0.289 20.008 0.026a 20.002 0.614
Precentral 20.008 0.096 20.008 0.016a 0.000 0.905
Superior frontal 20.002 0.513 20.006 0.020a 0.001 0.812
Supramarginal 20.006 0.275 20.011 0.016a 20.006 0.187
Validation study sample
Overall LGI 0.017 0.511 20.022 0.261 20.070 0.002a
Inferior parietal 0.012 0.693 20.045 0.061 20.065 0.020a
Postcentral 0.037 0.333 20.020 0.511 20.070 0.040a
Precentral 0.003 0.938 20.024 0.448 20.126 ,0.001a
Superior frontal 0.040 0.166 20.027 0.226 20.058 0.023a
Supramarginal 0.076 0.043a 20.015 0.595 20.064 0.054
Abbreviations: LGI 5 local gyrification index; PD 5 Parkinson disease; PDE 5 Parkinson disease–early; PDM 5 Parkinson disease–middle; PDL 5 Parkinson
disease–late.
a Statistically significant.
Neurology 86 March 22, 2016 1147
ª 2016 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
monitoring disease progression. Interestingly, we
found that the loss of gyrification was particularly
prominent in the neocortical regions that are thought
to be relatively spared from Lewy pathology in
PD.5,30 In contrast, we did not observe altered gyrifi-
cation in areas known to be more heavily affected by
Lewy pathology (i.e., brain base and temporal areas).
Taken together, these findings raise the possibility that
cortical folding abnormalities may reflect pathologic
processes not attributable solely to Lewy pathology.
Although recent data provided initial evidence that
gyrification of the cortex is reduced in PD (average
DOI ; 3.9 years),31 the association between cortical
folding and disease progression remained unclear.
Indeed, another recent study reported no differences
between patients with PD and controls, although there
were some areas of correlation between a composite
measure of disease progression that included dementia
in PD and cortical gyrification of the left middle fron-
tal, superior parietal, superior frontal, supramarginal,
lateral occipital, inferior parietal, and right superior
frontal and superior parietal areas.8 Whereas these find-
ings may have been attributable to the inclusion of
dementia (mean MMSE 5 18.3 in the PD dementia
group), our study excluded dementia at baseline. Par-
ticipants with PDE or PDM did not have reduced gyr-
ification at baseline, but demonstrated accelerated loss
of gyrification longitudinally. PDL had prominently
reduced gyrification bilaterally in several cortical areas
despite the lack of dementia (MMSE ; 28–29). Dis-
ease duration, LEDD, and motor scores also were asso-
ciated with reduced overall LGI in PD. Together, these
findings suggest that accelerated loss of cortical folding
occurs shortly after PD diagnosis and may be associ-
ated with disease progression prior to the occurrence of
dementia. Accordingly, metrics of cortical folding may
provide sensitive measurements to gauge ongoing cor-
tical neurodegeneration as PD progresses.
Previous studies have reported findings of wide-
spread cortical pathology in PD, including reduced lev-
els of neurotransmitters and tyrosine hydroxylase
immunoreactive interneurons,3,4 increased apoptotic
signaling,2 and Lewy pathology.5 Neocortical areas,
however, have been shown to be relatively spared from
Lewy pathology.5 The current study demonstrated that
the loss of gyrification is especially prominent in the
precentral and postcentral areas in PD, suggesting that
cortical gyrification might not reflect Lewy pathology
Figure 2 Relationships of baseline regional local gyrification index and clinical measurements among Parkinson disease (PD) participants in
the longitudinal cohort
Descriptive plots illustrate the relationship between regional local gyrification and clinical measurements among PD participants in the longitudinal cohort.
Center lines (black) and gray areas represent the moving average and 95% bootstrapped confidence region for local gyrification index as a function of clinical
measurements. The b and p values were obtained via multiple linear regression for each clinical variable. Two data points were not shown in the levodopa-
equivalent daily dose (LEDD) plots because they had LEDD .1,800 mg/d. LGI 5 local gyrification index; UPDRS 5 Unified Parkinson’s Disease Rating Scale.
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directly as we hypothesized. These differences may be
explained by several possibilities. First, Lewy pathology
may not be correlated with cell death equally through-
out all cortical regions. Second, Lewy pathology is
known to occur in distinct cortical layers in PD, pref-
erentially in deeper layers in the neocortical areas and
in superficial layers of the mesocortex.5 This differen-
tial pattern of pathology may contribute to the gyrifi-
cation losses observed in this study. Few details,
however, are available regarding the exact layer-
specific pattern of Lewy pathology, warranting further
investigation.5 Third, changes in underlying white
matter could result in altered cortical folding.32
To understand the stage-dependent changes of
gyrification in PD, we subdivided PD patients into
3 subgroups as we have done previously.33 The PDE
upper limit of DOI (1 year) was chosen to define PD
participants who had not received extended treat-
ment. PDL was defined as PD participants having
at least 5 years of disease duration for several reasons.
For example, nigrostriatal terminal labeling has been
suggested to reach a floor after approximately 5 years,1
although some data suggest that nigral cell death
continues,34 and dopamine levels certainly decline
throughout disease progression.35 Clinically, dyskine-
sias, cognitive decline, and dopamine-nonresponsive
symptoms tend to be more prominent after the first 5
years (honeymoon phase).36,37 These subgroup cate-
gorizations provided balanced subgroup sample sizes
that are powerful for equivalence testing.1,38,39 Inter-
estingly, the LGI continued to decline after 5 years
(figure e-2). We also repeated our analyses using
H&Y stage, with similar results (table e-1). There
were also inverse correlations between gyrification
indices and clinical measurements (LEDD and
UPDRS-III, figures 2 and 3). Together, our results
support the notion that gyrification is stage-
dependent and associated with PD progression.
The current study had several limitations.
Although the overall sample size is large, the sample
size for PD subgroup analysis was relatively small.
Larger sample sizes and longer follow-up of various
disease staging categories will be needed to generalize
these findings. In addition, as is common in longitu-
dinal studies, there was significant dropout in both
the PD and control groups. The total number of
Figure 3 Relationships of regional local gyrification index and clinical measurements among Parkinson disease (PD) participants in the
validation study sample
Descriptive plots illustrate the relationship between regional local gyrification and clinical measurements among PD participants in the validation study sam-
ple. Center lines (black) and gray areas represent the moving average and 95% bootstrapped confidence region for local gyrification index as a function of
clinical measurements. The b and p values were obtained via multiple linear regression for each clinical variable. Two data points were not shown in the
levodopa-equivalent daily dose (LEDD) plots because they had LEDD .1,800 mg/d. LGI 5 local gyrification index; UPDRS 5 Unified Parkinson’s Disease
Rating Scale.
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visits, however, did not differ between these groups.
There also may be considerable variability in clinical
severity and disease duration.40 However, we repeated
all of our analyses using H&Y staging and found
similar results (figure e-1).
The PDL group also had a relatively high male-to-
female ratio. Most relationships between LGI and
disease duration persisted when male and female par-
ticipants with PD were analyzed separately (table
e-1). Although the p values in table e-1 may give
the impression of discordant results among female
participants, the directions of the correlations were
the same for all regions regardless of sex or cohort.
Furthermore, we found no significant differences in
overall, inferior parietal, postcentral, precentral, supe-
rior frontal, or supramarginal LGI between male and
female controls, and sex had no effect on the rate of
LGI change in controls. Nevertheless, to minimize
any potential confounding effect, we included sex
in our statistical model. We also utilized “on” medi-
cation motor scores because some participants could
not tolerate “off”medication assessment. Of note, the
scores obtained in the practically defined “off” med-
ication state may not represent true “off” medication
symptoms, since some drugs may not completely
wash out. “On” medication scores may be more rep-
resentative of the levodopa-unresponsive components
of patient symptoms, which may be more closely
related to cortical findings. Finally, the study was val-
idated using the baseline data from another newly
established cohort, and the longitudinal data are not
yet available. Although the Parkinson’s Progression
Markers Initiative has longitudinal data, this cohort
only includes PD participants in very early stages.
Independent validation of longitudinal trajectories
in advanced stage PD is needed.
This study demonstrated that cortical gyrification
is reduced among participants with PD without
dementia, and is associated with measurements of
PD progression. Loss of cortical gyrification may be
accelerated shortly after PD diagnosis and becomes
prominent in later stages. These findings suggest that
folding metrics may be informative for quantifying
cortical changes throughout PD progression. More-
over, the finding of reduced gyrification in areas
known to be spared from Lewy pathology is unex-
pected, raising the possibility that cortical folding
abnormalities reflect processes not attributable solely
to Lewy pathology in PD.
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